- Home
- / Cytokinetics
Cytokinetics
Stock Price
$51.5
2024-10-29
Market Capitalization
$6.1 B
2024-10-29
Revenue
$88 M
FY, 2025
Cytokinetics Summary
Company Summary
- Overview
- Cytokinetics is a biopharmaceutical company developing medicines that impact the mechanics of muscle. It offers small molecule muscle activators and inhibitors to treat heart failure, hypertrophic cardiomyopathy, neuromuscular diseases, etc.
- Type
- Public
- Status
- Active
- Founded
- 1998
- HQ
- South San Francisco, CA, US | view all locations
- Website
- https://cytokinetics.com
- Cybersecurity rating
- ESG rating
- Sectors
Table of Contents
Key People
Daniel R Casper, Vice President, Information Technology
Andrew Callos, Executive Vice President, Chief Commercial Officer
Bonnie A Charpentier, Senior Vice President, Regulatory Affairs and Compliance
LocationsView all
2 locations detected
South San Francisco, CA HQ
United States
280 E Grand Ave
South San Francisco, CA
United States
350 Oyster Point Blvd
Cytokinetics Financials
Summary Financials
- Revenue (Q1, 2026)
- $19.4M
- Net income (Q1, 2026)
- ($206.0M)
- Cash (Q1, 2026)
- $129.8M
- EBIT (Q1, 2026)
- ($183.6M)
- Enterprise value
- $6.4B